SCHEMBL485753

SCHEMBL485753

C=CCCNC(=O)OCc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.66
LMNA P02545 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
HTT P42858 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.53
KEAP1 Q14145 2/20 0.53
NFE2L2 Q16236 2/20 0.53
MAPT P10636 1/20 0.52
SLC1A3 P43003 1/20 0.51
SLC1A1 P43005 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
KAT2B Q92831 1/20 0.48
GAA P10253 1/20 0.48
IDO1 P14902 1/20 0.48
TDO2 P48775 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6204298 0.91 TGM2 (0.71) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL22163638 0.86 TGM2 (0.61) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL736590 0.86 LMNA (0.67) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL5002848 0.86 LMNA (0.67) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL28612192 0.85 HTT (0.67) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL13055383 0.85 LMNA (0.80) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL195242 0.84 TGM2 (0.61) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL504964 0.83 TGM2 (0.64) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL6253000 0.83 LMNA (0.63) TGM2LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL30697760 0.83 TGM2 (0.86) TGM2LMNASMN1; SMN2HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2025-08-21 US disclosed
EP-4504724-A1 SPLEEN TYROSINE KINASE INHIBITORS Uniquest Pty Limited (AU) 2025-02-12 EP disclosed
US-12209102-B2 Heterocyclic compounds and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2025-01-28 US disclosed
EP-4489738-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Kumquat Biosciences Inc. (US) 2025-01-15 EP disclosed
US-20240425525-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-12-26 US disclosed
US-20240425522-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-12-26 US disclosed
WO-2023193054-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2023-10-12 WO disclosed
WO-2023193054-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2023-10-12 WO disclosed
WO-2023172737-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-09-14 WO disclosed
US-20190322668-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2019-10-24 US disclosed
US-8114867-B2 Oxazolidinone antibiotic derivatives ACTELION PHARMACEUTICALS LTD (CH) 2012-02-14 US disclosed
EP-2132174-B1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS MEDICINES CO LEIPZIG GMBH (DE) 2012-02-01 EP disclosed
EP-2132174-B1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS MEDICINES CO LEIPZIG GMBH (DE) 2012-02-01 EP disclosed
US-20100305090-A1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2010-12-02 US disclosed
US-20100305090-A1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2010-12-02 US disclosed
US-20100305090-A1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2010-12-02 US disclosed
US-20100137290-A1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-06-03 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
EP-2146987-A2 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-01-27 EP disclosed
WO-2008126024-A2 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 TGM2 3836/4885LMNA 201/4885SMN1; SMN2 4730/4885
US-20100137290-A1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES OXA1L, XDH, CCNY TGM2 4751/4885LMNA 2322/4885SMN1; SMN2 2745/4885
US-20240425522-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TP53, HRAS, KRAS TGM2 2193/4885LMNA 2570/4885SMN1; SMN2 1564/4885
US-20100305090-A1 META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS MMP7, DNPEP, METAP1 TGM2 352/4885LMNA 4194/4885SMN1; SMN2 2987/4885
US-20190322668-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT TGM2 1416/4885LMNA 2222/4885SMN1; SMN2 3979/4885
US-12209102-B2 Heterocyclic compounds and uses thereof TP53, HRAS, KRAS TGM2 2193/4885LMNA 2570/4885SMN1; SMN2 1564/4885
US-20240425525-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TP53, HRAS, KRAS TGM2 2193/4885LMNA 2570/4885SMN1; SMN2 1564/4885
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS LCK, BTK, SYK TGM2 2711/4885LMNA 4746/4885SMN1; SMN2 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.